Aspirin May Prevent Cholangiocarcinoma: A Case–Control Study from the United Kingdom
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The proliferation of cholangiocarcinoma cells is suppressed in cell culture by nonsteroidal antiinflammatory drugs (NSAIDs) through the inhibition of cyclo-oxygenase-2 enzyme and also by statins which decrease the production of mediators of the cell cycle.
To investigate whether there is an inverse association between NSAIDs, including aspirin, and the development of cholangiocarcinoma and, for the first time in a Western population, between statin use and the development of cholangiocarcinoma.
This epidemiological study had a case–control design in which cases of cholangiocarcinoma diagnosed in Norwich between 2004 and 2010 and in Leicester in 2007 were identified from clinical databases. Controls were patients with basal cell carcinomas treated in the respective dermatology departments. The case notes of all subjects were reviewed to confirm diagnoses and obtain information on medication use. The data were analyzed using unconditional logistic regression to calculate odds ratios (OR) with 95 % confidence intervals (CI).
In total, 81 cases of cholangiocarcinoma and 275 controls were identified. For all cases there was radiological evidence of cancer and 86 % of the cases involved the extrahepatic biliary system. Aspirin use was inversely associated with the development of cholangiocarcinoma (OR 0.45, 95 % CI 0.22–0.92), but there were no significant associations between the development of cholangiocarcinoma and NSAIDs (OR 0.39; 95 % CI 0.11–1.42) or statins (OR 0.58; 95 % CI 0.28–1.19).
The epidemiological data from this study support the biological evidence for aspirin having a protective effect against the development of cholangiocarcinoma. Aspirin use should be measured in future etiological studies and assessed as a chemoprevention agent in those at high risk of developing this type of cancer.
- Landis, SH, Murray, T, Bolden, S, Wingo, PA (1998) Cancer statistics, 1998 [Internet]. CA Cancer J Clin 48: pp. 6-29 CrossRef
- Khan, SA, Davidson, BR, Goldin, R, Pereira, SP, Rosenberg, WM, Taylor-Robinson, SD (2002) Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document [Internet]. GUT 51: pp. VI1-VI9 CrossRef
- West, J, Wood, H, Logan, RF, Quinn, M, Aithal, GP (2006) Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer 94: pp. 1751-1758 CrossRef
- Watanapa, P, Watanapa, WB (2002) Liver fluke-associated cholangiocarcinoma. Br J Surg 89: pp. 962-970 CrossRef
- Burak, K, Angulo, P, Pasha, TM, Egan, K, Petz, J, Lindor, KD (2004) Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 99: pp. 523-526 CrossRef
- Rosen, CB, Nagorney, DM, Wiesner, RH, Coffey, RJ, LaRusso, NF (1991) Cholangiocarcinoma complicating primary sclerosing cholangitis [Internet]. Ann Surg 213: pp. 21-25 CrossRef
- Bergquist, A, Broomé, U (2001) Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 15: pp. 643-656 CrossRef
- Sorensen, HT, Friis, S, Olsen, JH, Thulstrup, AM, Mellemkjaer, L, Linet, M (1998) Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 28: pp. 921-925 CrossRef
- Shaib, YH, El-Serag, HB, Davila, JA, Morgan, R, McGlynn, KA (2005) Risk factors of intrahepatic cholangiocarcinoma in the United States: a case–control study. Gastroenterology 128: pp. 620-626 CrossRef
- Yamamoto, S, Kubo, S, Hai, S, Uenishi, T, Yamamoto, T, Shuto, T (2004) Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma [Internet]. Cancer Sci 95: pp. 592-595 CrossRef
- Shin, HR, Lee, CU, Park, HJ, Seol, SY, Chung, JM, Choi, HC (1996) Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea [Internet]. Int J Epidemiol 25: pp. 933-940 CrossRef
- Kubo, S, Kinoshita, H, Hirohashi, K, Hamba, H (1995) Hepatolithiasis associated with cholangiocarcinoma [Internet]. World J Surg 19: pp. 637-641 CrossRef
- Zhu, AX, Lauwers, GY, Tanabe, KK (2004) Cholangiocarcinoma in association with Thorotrast exposure. J Hepatobiliary Pancreat Surg 11: pp. 430-433 CrossRef
- Grainge, MJ, West, J, Solaymani-Dodaran, M, Aithal, GP, Card, TR (2009) The antecedents of biliary cancer: a primary care case-control study in the United Kingdom. Br J Cancer 100: pp. 178-180 CrossRef
- Jing, W, Jin, G, Zhou, X, Zhou, Y, Zhang, Y, Shao, C (2012) Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev 21: pp. 24-31 CrossRef
- Han, C, Wu, T (2005) Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 280: pp. 24053-24063 CrossRef
- Boonmasawai, S, Akarasereenont, P, Techatraisak, K, Thaworn, A, Chotewuttakorn, S, Palo, T (2009) Effects of selective COX-inhibitors and classical NSAIDs on endothelial cell proliferation and migration induced by human cholangiocarcinoma cell culture [Internet]. J Med Assoc Thai 92: pp. 1508-1515
- Liu, E, Sakoda, LC, Gao, YT, Rashid, A, Shen, MC, Wang, BS (2005) Aspirin use and risk of biliary tract cancer: a population-based study in Shanghai, China. Cancer Epidemiol Biomark Prev 14: pp. 1315-1318 CrossRef
- Shimoyama, S (2011) Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemother Pharmacol 67: pp. 729-739 CrossRef
- Keyomarsi, K, Sandoval, L, Band, V, Pardee, AB (1991) Synchronization of tumor and normal cells from G1 to multiple cell cycles by Lovastatin [Internet]. Cancer Res 51: pp. 3602-3609
- Jakobisiak, M, Bruno, S, Skierski, JS, Darzynkiewicz, Z (1991) Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 1: pp. 3628-3632 CrossRef
- Kamigaki, M, Sasaki, T, Serikawa, M, Inoue, M, Kobayashi, K, Itsuki, H (2011) Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells. Int J Oncol 39: pp. 561-568
- World Health Organization. International statistical classification of diseases and related health problems. 10th revision. M8160/3.C. Geneva: World Health Oganization; 2007.
- American Joint Committee on Cancer (AJCC). AJCC cancer staging manual. 6th ed. New York, NY: Springer; 2006.
- Muller-Decker, K, Furstenberger, G (2007) The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog 46: pp. 705-710 CrossRef
- Dannenberg, AJ, Altorki, NK, Boyle, JO, Dang, C, Howe, LR, Weksler, BB (2001) Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2: pp. 544-551 CrossRef
- Bhutta HY, Clark A, Holt S, et al. Oesophageal cancer—an aetiological investigation into the potential protective effect of statins in the UK General Practice Research Database (GPRD). Gastroenterology 2011;60:A36-A37.
- Aspirin May Prevent Cholangiocarcinoma: A Case–Control Study from the United Kingdom
Digestive Diseases and Sciences
Volume 59, Issue 7 , pp 1567-1572
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Section of Molecular Gastroenterology, Leeds Institute of Molecular Medicine, St James’s University Hospital, Leeds, LS9 7TF, UK
- 2. Norfolk and Norwich University Hospital NHS Trust, Norwich, NR4 7UY, UK
- 3. Leicester General Hospital, Gwendolen Rd, Leicester, LE5 4PW, UK
- 4. Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK